Olmecip (Olmesartan Medoxomil Tablets)

Olmesartan Tablets

Clearsky Pharmacy

Olmecip (Olmesartan Medoxomil Tablets) is used alone or along with other medicines for the treatment of hypertension, to lower blood pressure in adults as well as children 6 years and older.

Olmecip Tablets

Clearsky Pharmacy

Olmecip Tablets are manufactured by Cipla Ltd., India.(Website: www.cipla.com)

Olmesartan Medoxomil Tablets Brand Names

Clearsky Pharmacy

Olmesartan Medoxomil tablets are available as Benicar, Olmecip, Olways, Benitec, Olarbi, Olmax 20, Olmesar-20, Olmetrack-20 and Zoltab-20.

Active Ingredient

Clearsky Pharmacy

The active ingredient contained in Olmecip tablets is Olmesartan Medoxomil. Each film-coated tablet contains 20 mg or 40 mg of Olmesartan Medoxomil.

Chemical Structure

Clearsky Pharmacy

The structure of Olmesartan Medoxomil is given below:

Uses of Olmecip Tablets

Clearsky Pharmacy

Olmecip (Olmesartan Medoxomil) is use for the treatment of mild to moderate essential hypertension. Olmecip may be used alone or in combination with thiazide diuretic. Olmesartan Medoxomil is an angiotensin II receptor antagonist which works by blocking the action of certain substances that tightens the blood vessels, thus allowing the blood to flow freely.

Storage Instructions

Clearsky Pharmacy

Olmecip (Olmesartan Medoxomil) have to be stored at controlled room temperature i.e. from 20C to 25C (68F to 77F) with excursions permitted between 15 to 30C (59 to 86F). Keep this as well as all other medicines away from children and pets.

Olmesartan Medoxomil Dosage

Clearsky Pharmacy

Treatment of Adult Hypertension: The dosage must be individualized. The usual recommended starting dose of Olmecip (Olmesartan Medoxomil) is 20 mg once daily when used as monotherapy in patients who are not volume-contracted.

For patients that require further reduction in blood pressure after 2 weeks of therapy, the dose of Olmecip may be increased to 40 mg.

The dosage of Olmecip tablets (Olmesartan Medoxomil) is given below:

Warnings

Clearsky Pharmacy

When pregnancy is detected, discontinue Olmecip (Olmesartan tablets) as soon as possible. Avoid fetal (in utero) exposure as medicines like Olmesartan Medoxomil that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Children below 1 year of age must not receive Olmecip for hypertension. Observe for signs and symptoms of hypotension in volume or salt-depleted patients with treatment initiation. Monitor for worsening renal function in patients with renal impairment.

Olmecip Tablets

Clearsky Pharmacy

Contraindications

Olmecip is contraindicated in patients with a hypersensitivity to Olmesartan Medoxomil or any other component of this medication. When pregnancy is detected, discontinue Olmecip (Olmesartan tablets) immediately.

Olmesartan Side Effects

Clearsky Pharmacy

The most common side effect of Olmecip (Olmesartan tablets) in adults was dizziness with an incidence rate of 3%.The other Olmesartan side effects with an incidence rate of 0.5% or more include:

Body as a Whole: Chest pain, peripheral oedema

Central and Peripheral Nervous System: Vertigo

Gastrointestinal: Abdominal pain, dyspepsia, gastroenteritis, nausea

Heart Rate and Rhythm Disorders: Tachycardia

Metabolic and Nutritional Disorders: Hypercholesterolaemia, hyperlipaemia, hyperuricaemia

Musculoskeletal: Arthralgia, arthritis, myalgia

Skin and Appendages: Rash.

Others: Facial oedema was reported in five patients receiving Olmesartan.

Olmesartan Overdose

Clearsky Pharmacy

The most likely symptoms of Olmecip (Olmesartan tablets) overdosage would be hypotension and tachycardia; bradycardia could be encountered if parasympathetic (vagal) stimulation occurs.

Olmecip Overdose

Clearsky Pharmacy

In case symptomatic hypotension occurs due to Olmecip overdose, supportive treatment should be started. The dialyzability of Olmesartan is not known.

Olmesartan During Pregnancy

Clearsky Pharmacy

Olmecip (Olmesartan Medoxomil Tablets) has been classified by the US FDA as Pregnancy Category D. The use of angiotensin II antagonists is not recommended during the first trimester of pregnancy. The use of angiotensin II antagonists is contraindicated during the 2nd and 3rd trimester of pregnancy. Use of medicines that act on the RAS during the second and third trimesters of pregnancy reduces foetal renal function and increases foetal and neonatal morbidity and death.

Olmecip Tablets

For more details on Olmecip Tablets click here

Clearsky Pharmacy

Olmecip (Olmesartan Medoxomil Tablets) by Cipla Limited, India.